Logo image
Back
CA Inhibitor 1 Treatment Does Not Affect Estrous Cyclicity in Mice
Journal article   Open access   Peer reviewed

CA Inhibitor 1 Treatment Does Not Affect Estrous Cyclicity in Mice

Laura L Giacometti, Donna Mae Dalere, Bupe Lwamba, Samuel L Goldberg, Kaitlyn Feliciano and Jacqueline M Barker
Journal of Neuroimmune Pharmacology, v 21(1), 24
09 May 2026
DOI: https://doi.org/10.1007/s11481-026-10293-y
PMID: 42105019
Featured in Collection :   Drexel's Newest Publications
url
https://doi.org/10.1007/s11481-026-10293-yView
Published, Version of Record (VoR) Open Access via Drexel Libraries Read and Publish Program 2026 Open CC BY V4.0

Abstract

Pre-exposure prophylaxis Estrous cycle MPOA Astrocytes
Approximately 45% of new HIV infections worldwide occur in women and girls and adherence to pre-exposure prophylaxis (PrEP) to prevent HIV infection is limited, particularly in women. Long-acting PrEP such as lenacapavir may improve adherence. One barrier to PrEP usage in women and girls is impact on the menstrual cycle, though impacts of long-acting PrEP are unclear. To model the effect of lenacapavir administration on cyclicity, adult female C57Bl/6J mice were injected with capsid (CA) inhibitor, an analog of lenacapavir, 1 and assessed for estrous cyclicity. Injection of either CA inhibitor 1 did not impact estrous cycle. CA inhibitor 1 did not impact astrocyte immunoreactivity or chronic cellular activity in the medial preoptic area (mPOA), a major regulator of the estrous cycle. These findings warrant further investigation into the effects of lenacapavir on menstrual cycle as it may promote PrEP adherence for those concerned with PrEP impacts on menstrual cycle.

Metrics

1 Record Views

Details

Logo image